Head to head
Pemvidutide against Survodutide
Two investigational GLP-1 and glucagon dual agonists being developed for overlapping indications in obesity and metabolic liver disease. Same mechanism, different sponsors, no head to head.
Column A
PemvidutidePemvidutide (GLP-1 / glucagon dual agonist)
Altimmune's GLP-1 and glucagon dual agonist being developed for obesity and metabolic liver disease, with a focus on preserving lean mass.
Column B
SurvodutideSurvodutide (GLP-1 / glucagon dual agonist)
An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Side by side, on the facts we can check
| Attribute | Pemvidutide | Survodutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (Phase 3 PERFORMA in MASH started August 2026; FDA Breakthrough Therapy designation for MASH) | Investigational, not FDA-approved |
| Half-life | Supports weekly dosing | ~6 days |
| Molecular weight | 3,873.4 Da | ~4,900 Da |
| Mechanism | Agonizes GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure and reduced liver fat. | Agonizes both GLP-1 and glucagon receptors, combining appetite suppression and improved glucose handling with increased energy expenditure and hepatic fat reduction. |
| Human studies cited | 3 | 3 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Pemvidutide and Survodutide?
Pemvidutide: Altimmune's GLP-1 and glucagon dual agonist being developed for obesity and metabolic liver disease, with a focus on preserving lean mass. Survodutide: An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Which has stronger research evidence, Pemvidutide or Survodutide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Pemvidutide profile were human work, against 3 of 3 for Survodutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Pemvidutide and Survodutide FDA-approved?
Pemvidutide: Investigational (Phase 3 PERFORMA in MASH started August 2026; FDA Breakthrough Therapy designation for MASH). Survodutide: Investigational, not FDA-approved.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.